Completed
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
NCT05524545· Phase 1· ALX Oncology Inc.· Source
Terminated
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT05119335· Phase 1/2· NiKang Therapeutics, Inc.· Source
Completed
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
NCT04689828· Phase 3· Novartis Pharmaceuticals· Source
Terminated
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
NCT04551066· Phase 3· Incyte Corporation· Source
Completed
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
NCT04484142· Phase 2· Daiichi Sankyo· Source
Terminated
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
NCT04698187· Phase 2· Regeneron Pharmaceuticals· Source
Terminated
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
NCT04695977· Phase 2/3· Regeneron Pharmaceuticals· Source
Completed
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
NCT04696055· Phase 2· Bayer· Source
Completed
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
NCT03776071· Phase 3· Denovo Biopharma LLC· Source
Completed
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
NCT04466891· Phase 2· Jazz Pharmaceuticals· Source
Completed
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant
NCT04224272· Phase 2· Jazz Pharmaceuticals· Source
Completed
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
NCT03915951· Phase 2· Pfizer· Source
Completed
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
NCT03971474· Phase 2· SWOG Cancer Research Network· Source
Completed
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
NCT03752398· Phase 1· Xencor, Inc.· Source
Completed
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT03845296· Phase 2· SWOG Cancer Research Network· Source
Completed
Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
NCT03694002· Phase 2· SWOG Cancer Research Network· Source
Completed
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
NCT03740529· Phase 1/2· Loxo Oncology, Inc.· Source
Completed
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.
NCT03815058· Phase 2· Genentech, Inc.· Source
Terminated
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
NCT03616470· Phase 3· GlycoMimetics Incorporated· Source
Completed
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
NCT03377491· Phase 3· NovoCure Ltd.· Source
Completed
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
NCT03425279· Phase 1/2· BioAtla, Inc.· Source
Completed
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
NCT03289962· Phase 1· Genentech, Inc.· Source
Completed
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
NCT03274492· Phase 3· Hoffmann-La Roche· Source
Completed
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
NCT03201965· Phase 3· Janssen Research & Development, LLC· Source
Completed
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
NCT03037385· Phase 1/2· Hoffmann-La Roche· Source
Completed
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
NCT02956382· Phase 1/2· Georgetown University· Source
Completed
The National Myelodysplastic Syndromes (MDS) Study
NCT02775383· National Heart, Lung, and Blood Institute (NHLBI)· Source
Completed
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
NCT02675231· Phase 2· Eli Lilly and Company· Source
Completed
Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer
NCT02566772· Phase 1· Taiho Oncology, Inc.· Source
Completed
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
NCT02360579· Phase 2· Iovance Biotherapeutics, Inc.· Source
Completed
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
NCT01996865· Phase 3· Celgene· Source
Completed
S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer
NCT01959139· Phase 1/2· SWOG Cancer Research Network· Source
Completed
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
NCT01740427· Phase 3· Pfizer· Source
Completed
Abatacept as GVHD Prophylaxis Phase 2
NCT01743131· Phase 2· Boston Children's Hospital· Source
Completed
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery
NCT01101451· Phase 3· GOG Foundation· Source
Completed
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
NCT00980954· Phase 3· Radiation Therapy Oncology Group· Source